Open AccessAllogeneic hematopoietic SCT for primary cutaneous T cell lymphomas
Author(s) -
Vikram R. Paralkar,
Sunita Dwivedy Nasta,
Kelly Morrissey,
Jacqueline Smith,
Pavel Vassilev,
Mary Ellen Martin,
Steven C. Goldstein,
Alison W. Loren,
Alain H. Rook,
Ellen J. Kim,
David Porter
Publication year - 2011
Publication title -
bone marrow transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 127
eISSN - 1476-5365
pISSN - 0268-3369
DOI - 10.1038/bmt.2011.201
Subject(s) - medicine , hematopoietic stem cell transplantation , lymphoma , mycosis fungoides , transplantation , immunosuppression , chemotherapy , refractory (planetary science) , regimen , oncology , graft versus host disease , gastroenterology , surgery , physics , astrobiology
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas that are considered incurable. The role of allogeneic hematopoietic SCT (HSCT) in the treatment of CTCL is not well defined but may provide potent graft-vs-lymphoma (GVL) activity independent of the conditioning therapy. We present outcomes of 12 extensively-pretreated patients with CTCL who underwent allogeneic HSCT using, most commonly, a reduced intensity conditioning regimen. Median age at diagnosis of CTCL was 49 years, and median time to transplantation from diagnosis was 3.3 years. Transplantation induced and maintained CR in six patients with active disease, supporting the presence of a GVL effect. TRM was low, and 42% of patients were alive and disease-free a median duration of 22 months after transplant. Two patients showed strong and direct evidence of a GVL-effect with a direct response to withdrawal of immunosuppression or to donor leukocyte infusion. Our data show that HSCT can provide long-term disease control in patients with advanced CTCL, which otherwise was refractory to immunotherapy and chemotherapy.